Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

Federal judge sentences Houston man for selling fake cancer-fighting drug.

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

A 45-year-old man has been sentenced to prison for his role in selling tens of thousands of dollars' worth of counterfeit ...

A Houston federal judge has sent a counterfeit cancer drug seller to prison for nearly four years after investigators discovered vials labeled as Keytruda that contained no real cancer-fighting ...

A 45-year-old Indian national has been sentenced to 43 months in prison for conspiring to sell tens of thousands of dollars’ worth of counterfeit cancer medication that he privately compared to “just ...

Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...

The Food and Drug Administration is due to make an approval decision on injectable Keytruda by mid-September in a move that could bolster Merck's biggest franchise and downtrodden Merck stock.

Merck MRK along with partner Eisai announced data from the phase III LEAP-015 study, which evaluated blockbuster PD-1 inhibitor, Keytruda (pembrolizumab) and Eisai’s TKI inhibitor, Lenvima (lenvatinib ...

KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American ...

- Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing ...